Bozec, Erwan

Bresso, Emmanuel

Brunner La Rocca, Hans-Peter

Clark, Andrew L.

Cleland, John G.F.

Delles, Christian

Edelmann, Frank

Ferreira, Joao Pedro

Girerd, Nicolas

González, Arantxa

Heymans, Stephane

Huttin, Olivier

Kevin, Duarte

Kobayashi, Masatake

Pellicori, Pierpaolo

Petutschnigg, Johannes

Rossignol, Patrick

Verdonschot, Job A.J.

Zannad, Faiez

Aims:

High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characteristics associated with left atrial volume indexed by body surface area (LAVi), and whether LAVi influences the response to spironolactone on biomarker expression and clinical variables.



Methods and results:

In the HOMAGE trial, where people at risk of heart failure were randomized to spironolactone or control, we analysed 421 participants with available LAVi and 276 proteomic measurements (Olink) at baseline, month 1 and 9 (mean age 73 ± 6 years; women 26%; LAVi 32 ± 9 ml/m2). Circulating proteins associated with LAVi were also assessed in asymptomatic individuals from a population-based cohort (STANISLAS; n = 1640; mean age 49 ± 14 years; women 51%; LAVi 23 ± 7 ml/m2). In both studies, greater LAVi was significantly associated with greater left ventricular masses and volumes. In HOMAGE, after adjustment and correction for multiple testing, greater LAVi was associated with higher concentrations of matrix metallopeptidase-2 (MMP-2), insulin-like growth factor binding protein-2 (IGFBP-2) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (false discovery rates [FDR] &lt;0.05). These associations were externally replicated in STANISLAS (all FDR &lt;0.05). Among these biomarkers, spironolactone decreased concentrations of MMP-2 and NT-proBNP, regardless of baseline LAVi (pinteraction &gt; 0.10). Spironolactone also significantly reduced LAVi, improved left ventricular ejection fraction, lowered E/e', blood pressure and serum procollagen type I C-terminal propeptide (PICP) concentration, a collagen synthesis marker, regardless of baseline LAVi (pinteraction &gt; 0.10).



Conclusion:

In individuals without heart failure, LAVi was associated with MMP-2, IGFBP-2 and NT-proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size

Enlighten

Proteomic profiles of left atrial volume and its influence on response to spironolactone: findings from the HOMAGE trial and STANISLAS cohort

Proteomic profiles of left atrial volume and its influence on response to spironolactone: findings from the HOMAGE trial and STANISLAS cohort

Abstract

Similar works

Full text

Available Versions

Enlighten